Rifaximin
Treatment for Irritable Bowel Syndrome
Typical Dosage: 550 mg orally three times daily for 14 days
Effectiveness
65%
Safety Score
70%
Clinical Trials
24
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanideā ļø
Methš
Cigarettesš¬
Chemoā¢ļø
Alcoholšŗ
Morphineš
Antibioticsš
Tylenolš
Exerciseš
Waterš§
70
DangerousModerateSafe
Treatment Details
Dosage Range
550 mg orally three times daily for 14 days
Time to Effect
1-2 weeks
Treatment Duration
14-day course, potentially repeated for recurrence
Evidence Quality
HIGHNumber Needed to Treat (NNT)
8(Treat 8 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
100(Treat 100 patients to see 1 additional serious adverse event)
Confidence Score
88%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$18,000
Monitoring:$200
Side Effect Mgmt:$150
Total Annual:$18,350
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$120,000/QALY
QALYs Gained
0.07
Outcome-Based Costs
Cost per Responder
$61,167
Cost per Remission
$183,500
Comparison vs Loperamide
Cost Difference
+$17,800/year
More expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
No dominance
Prescription Access Economics
Annual Societal Loss per Patient
$14,510
Cost of prescription-only barriers (visits, time, admin, price premium)
Physician Visit Cost
$250/year
Time Cost
$120/year
Travel + wait time
Insurance Admin Cost
$40/year
Prior auth, claims
Rx Price
$18,000/year
Potential OTC Price
$3,600/year
Estimated if OTC available
Early Treatment Benefit
+0.05 QALYs
From faster OTC access
Risk Assessment
Misuse Risk
LOWMissed Diagnosis Risk
MODERATERifaximin Outcomes
for Irritable Bowel Syndrome
Efficacy Outcomes
Overall Effectiveness
+65%
Response Rate
+30%
Remission Rate
+10%
Common Side Effects
Nausea
+14%
Abdominal pain
+7%
Diarrhea
+5%
Sources:
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
13 completed trials for Rifaximin in Irritable Bowel Syndrome
Rifaximin for the Treatment of Irritable Bowel Syndrome
NCT00259155COMPLETEDPHASE2
92 participants
INTERVENTIONAL
Started: Jul 1, 2003
Study to Assess the Efficacy and Safety of Rifaximin Administered BID in the Treatment of Patients With Diarrhea-Associated Irritable Bowel Syndrome
NCT00269412COMPLETEDPHASE2
525 participants
INTERVENTIONAL
Scottsdale, United States +66 more
Started: Dec 1, 2005
Irritable Bowel Syndrome With Diarrhea (IBS-D) Rifaximin Re-Treatment Study
NCT01543178COMPLETEDPHASE3
2.58K participants
INTERVENTIONAL
Anniston, United States +295 more
Started: Feb 1, 2012
Hydrogen Breath Test an Instrument to Predict Rifaximin-Response in Irritable Bowel Syndrome Predominant Diarrhea
NCT03729271COMPLETEDPHASE4
148 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Jan 9, 2020
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00731679COMPLETEDPHASE3
623 participants
INTERVENTIONAL
Hueytown, United States +95 more
Started: Jul 1, 2008
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
NCT00724126COMPLETEDPHASE3
637 participants
INTERVENTIONAL
Anniston, United States +87 more
Started: Jul 1, 2008
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
NCT03219528COMPLETEDPHASE4
74 participants
INTERVENTIONAL
Ann Arbor, United States
Started: Feb 13, 2018
Changes in Microbiota and Metabolomic Profile Between Rifaximin Responders and Non-responders In Diarrhoea-Predominant Irritable Bowel Syndrome
NCT03557788COMPLETEDPHASE4
33 participants
INTERVENTIONAL
Singapore, Singapore
Started: May 7, 2018
The Efficacy of Probiotics as an Adjunct to Treatment of SIBO With Rifaximin
NCT06223685COMPLETEDNA
129 participants
INTERVENTIONAL
Szczecin, Poland
Started: Apr 1, 2023
Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
NCT00945334COMPLETEDNA
37 participants
INTERVENTIONAL
Los Angeles, United States +1 more
Started: Aug 1, 2009
Efficacy and Safety of Rifaximin With NAC in IBS-D
NCT04557215COMPLETEDPHASE1, PHASE2
45 participants
INTERVENTIONAL
Los Angeles, United States
Started: Nov 13, 2020
To Compare the Efficacy of Drugs in Combination for Treating Irritable Bowel Syndrome Associated With Diarrhea
NCT05867550COMPLETEDPHASE4
162 participants
INTERVENTIONAL
Karachi, Pakistan
Started: Jan 3, 2023
Gulf War Digestive Health Study
NCT00680836COMPLETEDNA
54 participants
INTERVENTIONAL
Salt Lake City, United States
Started: Oct 1, 2007
Showing 20 of 24 total trials